This Article Abstract Full Text Full Text (PDF) View Related Cardiosource Journal Scan Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Blair, J. E.A. Search for Related Content PubMed Articles by Blair, J. E.A. Related Collections Related Articles

Continental Differences in Clinical Characteristics, Management, and Outcomes in Patients Hospitalized With Worsening Heart Failure

Results From the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) Program

John E.A. Blair, MD^_*, Faiez Zannad, MD, Marvin A. Konstam, MD, FACC, Thomas Cook, PhD, Brian Traver, MS, John C. Burnett, Jr, MD^||, Liliana Grinfeld, MD, FACC^¶, Holly Krasa, MS^#, Aldo P. Maggioni, MD^_**, Cesare Orlandi, MD, FACC^#, Karl Swedberg, MD, PhD, FACC, James E. Udelson, MD, FACC, Christopher Zimmer, MD^#, Mihai Gheorghiade, MD, FACC^_*,_* for the EVEREST Investigators

^_* Northwestern University Feinberg School of Medicine, Chicago, Illinois
Institut National de la Santé et de la Recherche Médicale (INSERM), Nancy, France
Tufts-New England Medical Center, Boston, Massachusetts
University of Wisconsin, Madison, Wisconsin
^|| Mayo Clinic, Rochester, Minnesota
^¶ Hospital Italiano, Buenos Aires, Argentina
^# Otsuka Maryland Research Institute, Rockville, Maryland
^_** Associazione Nazionale Medici Cardioligi Ospedalieri Research Center, Florence, Italy
Sahlgrenska University Hospital/Östra, Gothenburg, Sweden

View larger version (20K): [in this window] [in a new window] [Download PPT slide]   Figure 1 Kaplan-Meier Analysis for Cumulative Mortality by Region EE = Eastern Europe; NA = North America; SA = South America; WE = Western Europe.

View larger version (19K): [in this window] [in a new window] [Download PPT slide]   Figure 2 Kaplan-Meier Analysis for Cardiovascular Mortality or HF Hospitalization by Region HF = heart failure; other abbreviations as in Figure 1.

View larger version (11K): [in this window] [in a new window] [Download PPT slide]   Figure 3 Weight Loss on Day 7 or Discharge Group A = tolvaptan; group B = placebo.

View larger version (12K): [in this window] [in a new window] [Download PPT slide]   Figure 4 Global Clinical Status on a Visual Analog Scale on Day 7 or Discharge Group A = tolvaptan; group B = placebo.